Semax

Plain-English version: Semax is a small protein fragment (a "peptide") that Russian scientists designed by borrowing a piece of a natural hormone called ACTH, then tweaking it so it lasts longer in the body and keeps only the brain-helping effects. The result is a compound studied for attention, memory, and protecting nerve cells — used in Russia as a simple nasal spray.

The story starts in the 1980s with a research team led by Nikolai Myasoedov at the Institute of Molecular Genetics in Moscow. Their starting point was ACTH(4-10) — a seven-amino-acid stretch of adrenocorticotropic hormone that improved attention and memory in animal studies without the adrenal-stimulating (cortisol-raising) effects of the full hormone. The catch: natural ACTH(4-10) breaks down in the body within minutes. The Semax modification adds a Pro-Gly-Pro tail to the end of the sequence, which dramatically slows that breakdown and gives the peptide a usable duration of action. The originators reviewed this design work after 15 years of study.^[10]

The finished sequence is Met-Glu-His-Phe-Pro-Gly-Pro. In Russia, Semax has held regulatory approval since 1996 for three uses: (1) cognitive and intellectual-mnestic (memory) disorders, (2) recovery from ischemic stroke and transient ischemic attack (TIA, a "mini-stroke"), and (3) optic-nerve conditions. It is sold as a 0.1% nasal spray (the lower-dose cognitive formulation) and a 1% nasal spray (the higher-dose neurological formulation).

The credibility caveat, stated up front: approval in one country under an older regulatory framework is not the same as the kind of large, modern, placebo-controlled Western trial most skeptics want to see — and no such trial exists for Semax. In the US it is not FDA-approved for anything and is sold only as a research compound. We cover the 2026 regulatory situation in detail in the Sourcing & Quality section below. For the broader legal picture, see Are Peptides Legal?

Takeaway first: Semax doesn't have one single switch. In animal and cell studies it nudges several brain systems at once — most clearly, it raises the levels of "growth factors" that help neurons survive and form new connections. Here is what the verified research actually shows, and where it stops.

1. Raising BDNF and NGF — the growth-factor mechanism (best-supported)

BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) are proteins your brain uses to keep neurons alive and to build new synaptic connections — the physical basis of learning and memory. The clearest finding in the Semax literature is that it increases these factors. In rats, Semax up-regulated both BDNF and its receptor TrkB in the hippocampus, the brain's main memory hub.^[1] Follow-up work mapped the timing of this effect, showing Semax raises NGF and BDNF gene expression across the hippocampus, frontal cortex, and even the retina, with a time-dependent pattern rather than a single spike.^[2][3] Evidence level: rats. This is the molecular story behind nearly every "nootropic" claim made about Semax.

2. Neuroprotection after low blood flow (ischemia)

"Ischemia" means tissue starved of blood and oxygen — what happens in a stroke. Using genome-wide analysis in a rat model of focal brain ischemia, researchers found Semax broadly shifts brain gene expression, especially genes tied to the immune and vascular (blood-vessel) systems.^[4] A later transcriptome study in a rat ischemia-reperfusion model (blood flow cut off, then restored, which is when much of the damage occurs) reported protective effects at the gene-expression level.^[5] These findings are the mechanistic backbone of Russia's stroke approval — but again, they are in rodents.

3. Anti-stress, mood-related signaling

Semax belongs to the melanocortin family of peptides. In male rats exposed to acute stress, Semax and related melanocortin derivatives corrected disrupted gene-expression patterns in the hippocampus — a proposed route to its reported effects on stress resilience and drive.^[6] This is a plausible, published mechanism, but it does not establish that Semax treats any mood or anxiety disorder in humans. For anxiety specifically, its sister peptide Selank is the better-matched compound.

4. Why the nose? Direct nose-to-brain delivery

Semax is used intranasally because the nasal passage offers a partial shortcut to the brain along the olfactory pathway. In rats, intranasal Semax was measured penetrating into both brain tissue and blood, supporting this "nose-to-brain" route as more than marketing.^[7] Note: specific human numbers you may see quoted (for example, "peak plasma in 4 minutes") are not backed by a verified human pharmacokinetic study we could locate — treat those precise figures as unconfirmed.

What we do NOT know

There is no fully characterized human receptor target, no reliable published human pharmacokinetics, and no modern human dose-response data. The claim that Semax "does not raise cortisol" is mechanistically reasonable — it lacks the corticotropic portion of ACTH by design — but we could not find a specific verified human cortisol-measurement study to prove it, so it is best presented as a design rationale rather than settled human fact. The mechanisms above are real published findings, but they are overwhelmingly from rats and cell cultures, and mechanism in animals does not guarantee benefit in people.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. Semax has a genuinely mixed evidence base — some real human data in stroke, and mostly animal or hard-to-verify data everywhere else. We flag which is which honestly.

Ischemic stroke recovery (the strongest human evidence)

Claim: may improve neurological recovery when given soon after an ischemic stroke. Mechanism: neuroprotection via BDNF up-regulation and favorable shifts in immune/vascular gene expression at the injury site. Population: humans — patients in the acute period of hemispheric ischemic stroke. Effect: the Gusev/Skvortsova/Myasoedov clinical program reported improved neurological and electrophysiological (EEG) outcomes when Semax was given during the acute phase; this study underpins Russia's approval of the 1% nasal spray for stroke.^[8] Limitation: the accessible abstract does not report a quantified effect size, the trial is decades old and Russian-language, and there is no large modern Western replication. This is real human evidence, but not the gold-standard trial a skeptic would want.

Chronic cerebrovascular insufficiency

Claim: may slow decline in people with reduced chronic brain blood flow. Mechanism: ongoing neurotrophic and vascular support. Population: humans with cerebrovascular insufficiency. Effect: Gusev, Skvortsova, and Chukanova reported that Semax reduced disease progression and the frequency of exacerbations.^[9] Limitation: again older Russian clinical data with limited methodological detail available in the indexed abstract.

Cognitive enhancement (attention, memory) — the popular but weakly verified use

Claim: sharper attention and working memory in healthy adults, especially under high mental load. Mechanism: BDNF/NGF up-regulation supporting synaptic plasticity. Population: mostly rodents; human cognitive claims are frequently attributed to a 1996 Russian paper we could not locate or verify in PubMed this run. Effect: in rat models, Semax has been associated with better learning and memory performance, consistent with its growth-factor mechanism.^[1][2] Limitation — read this carefully: the widely repeated idea that Semax reliably boosts focus and memory in healthy people is not supported by a verifiable human trial we could confirm. The honest framing is: strong molecular rationale, animal support, but thin verified human efficacy data for cognitive enhancement.

Neuroprotection and stress resilience

Claim: protects neurons and helps the brain cope with stress. Mechanism: anti-apoptotic and anti-stress gene-expression changes; correction of stress-disrupted hippocampal signaling. Population: rats. Effect: genome-wide studies show protective transcriptome changes after ischemia-reperfusion, and melanocortin peptides including Semax corrected stress-induced gene patterns.^[5][6] Limitation: preclinical only; do not extrapolate to treating human anxiety, depression, or neurodegenerative disease.

Optic-nerve conditions

Claim: may support the optic nerve and retina. Mechanism: NGF-mediated support of retinal ganglion cells; Semax raises NGF/BDNF in the retina in animals. Population: used in Russian clinical practice for optic-nerve atrophy; supporting molecular data is from rats.^[2] Limitation: this indication rests on clinical practice and animal mechanism rather than verifiable controlled human trials.

The honest bottom line on "benefits"

• Stroke is the best-supported use and even there the human data are old, Russian-language, and not quantified in accessible abstracts.^[8]
• The cognitive-enhancement reputation outruns the verified evidence. Much of it traces to animal work and papers that could not be independently confirmed.
• No large modern Western RCT exists for any Semax indication.
• Anecdotes are not data. Enthusiastic user reports of "clean focus" cannot substitute for controlled trials.

Read this first: the most rigorously documented Semax dosing comes from the Russian approved nasal-spray protocols, and Western research-community protocols are derived from those. There is no modern Western human dosing trial. We describe these doses for completeness and harm reduction, not as medical guidance — Semax is not an approved drug in the US.

Dosing by application (from Russian approved protocols)

Application	Formulation	Total daily dose	Frequency	Course length
Cognitive support (healthy / mild impairment)	0.1% nasal spray	200–600 mcg	2–3 drops per nostril, 2–3× daily	10–14 days
Cognitive impairment / mild dementia	0.1% nasal spray	600–900 mcg	3 drops per nostril, 3× daily	14 days; can repeat after a rest
Acute ischemic stroke (hospital protocol)	1% nasal spray	9–18 mg	3 drops per nostril, 3–4× daily	10–14 days
TIA / mild stroke recovery	1% nasal spray	3–6 mg	2–3 drops per nostril, 3× daily	10–14 days
Subcutaneous (research)	Reconstituted solution	200–1,000 mcg	Once or twice daily	10–14 days

As a rough reference, one drop of the 0.1% spray delivers about 50 mcg and one drop of the 1% spray about 500 mcg. The 10× range between cognitive and neurological uses reflects Semax's well-characterized dose ladder — low doses for everyday cognitive support, much higher doses reserved for active neurological pathology under medical care.^[8]

Why intranasal is the primary route

Every Russian approved protocol uses the nasal spray. The olfactory pathway gives partial direct nose-to-brain delivery, which is why the spray is favored over injection; rat studies confirm intranasal Semax reaches brain tissue.^[7] Good technique matters: tilt the head back slightly, place drops on the inner upper wall of the nostril (not down the throat), stay still for about 30 seconds, alternate nostrils across doses, and avoid blowing your nose for 15 minutes afterward. If congested, a saline rinse 15 minutes beforehand improves absorption.

Subcutaneous route and reconstitution math

Subcutaneous (SC) injection is the less common research route. It requires reconstituting the freeze-dried (lyophilized) powder with bacteriostatic water. The core formula:

Concentration (mg/mL) = vial amount (mg) ÷ water added (mL)

Worked example: take a 10 mg vial and add 2 mL of bacteriostatic water. That gives 10 ÷ 2 = 5 mg/mL, i.e. 5,000 mcg per mL. To draw a 500 mcg dose: 500 ÷ 5,000 = 0.10 mL, which is 10 units on a standard 100-unit insulin syringe. A 250 mcg dose is 0.05 mL, or 5 units.

Vial	BAC water	Concentration	250 mcg	500 mcg
10 mg	2 mL	5.0 mg/mL	0.05 mL (5 units)	0.10 mL (10 units)
5 mg	2 mL	2.5 mg/mL	0.10 mL (10 units)	0.20 mL (20 units)
5 mg	1 mL	5.0 mg/mL	0.05 mL (5 units)	0.10 mL (10 units)

Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for step-by-step technique.

Timing and cycling

• Dose early: Semax is mildly activating, so confine all doses to before roughly 2:00 PM. Evening doses can interfere with sleep onset in sensitive people.
• Be consistent: take doses at the same times each day for steadier levels across a course.
• Standard course: 10–14 days, matching the Russian clinical protocols, followed by 7–14 days off. For chronic cognitive concerns, Russian protocols sometimes repeat 2–3 courses with rests between.
• Avoid open-ended daily use: long-term continuous dosing in healthy adults is poorly characterized in the published literature.

None of the above is a recommendation to self-administer an unapproved compound — it is a description of how the research and approved-product doses are structured.

Straight talk: in Russia's clinical use, Semax has a reputation for being well tolerated over short courses, and the most consistent complaints are minor and nasal-related. But there is an important honesty caveat: we could not locate a dedicated, verifiable Semax safety or toxicity study in PubMed this run. What safety information exists is embedded inside the Russian stroke and cerebrovascular clinical reports.^[8][9] So "well tolerated" is a reasonable summary of clinical experience, not a claim backed by modern controlled safety trials.

Reported side effects by frequency

Effect	Frequency	Route	Notes
Mild nasal irritation / dryness	Common (~5–10%)	Intranasal	Resolves within minutes; tends to ease over the first week
Transient nasal taste / drainage	Common	Intranasal	Normal physiological response to a nasal spray
Sleep disturbance if dosed late	Uncommon	Both	Move all doses to morning / early afternoon
Mild headache (first week)	Uncommon	Both	Usually self-resolves; reduce dose if it persists
Overstimulation / jitteriness	Uncommon	Both	Reduce dose or frequency
Injection-site redness	Common at site	Subcutaneous only	Mild; rotate sites
Allergic reaction	Rare	Both	Discontinue and seek evaluation

The cortisol question

You will often read that Semax "does not raise cortisol" or "does not touch the stress axis." Here is the accurate version: Semax was designed to lack the corticotropic portion of ACTH, so it is mechanistically reasonable that it does not stimulate cortisol.^[10] This is a genuine and important design feature that separates it from its parent hormone. However, we could not find a specific verified human study measuring cortisol before and after Semax to prove the absence of effect. Treat "no cortisol effect" as strong design rationale, not fully proven human data.

Contraindications and interactions (mostly theoretical)

• Pregnancy and breastfeeding: no controlled safety data — avoid.
• Acute psychiatric states: use caution in mania, acute psychosis, or severe anxiety, since the activating effect could amplify symptoms.
• Seizure disorders: not a strict contraindication, but any CNS-active compound warrants neurology oversight here.
• Drug interactions: no well-characterized CYP450 (liver-enzyme) interactions are established. Additive effects with stimulants (caffeine, ADHD medications) are theoretically plausible given the activating profile. These are cautions from first principles, not documented interaction reports.

What to do if you experience side effects

• Nasal irritation: a saline rinse before dosing can help; reduce concentration if needed.
• Sleep disruption: shift all doses before 2:00 PM and reduce the total daily amount.
• Headache or overstimulation: cut the dose by half for a few days, or pause for 3–5 days and restart lower.
• Allergic reaction: discontinue immediately and seek medical evaluation.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: in the US, Semax is an unregulated research compound, so purity and identity vary widely between suppliers. For an unproven peptide, contamination can be a bigger practical risk than the compound itself. Knowing how to read a Certificate of Analysis (COA) is the single most useful skill here.

What a credible product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected Semax molecular weight.
• Batch-specific results: the COA should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial.

Red flags: no COA (or a seller-issued one rather than an independent lab), pre-mixed "ready to use" liquid, prices far below market, and explicit human-use or medical claims, which signal a non-compliant, higher-risk vendor.

US legal and regulatory status (2026)

This is where the honest framing really matters, because a lot of online copy overstates it.

• Not FDA-approved for any indication. Semax has no NDA/ANDA and no OTC monograph in the US; it is a research-only compound.
• Approved in Russia since 1996 as a 0.1% and 1% intranasal spray for cognitive disorders, ischemic stroke/TIA, and optic-nerve conditions — but a foreign approval does not confer any US legal status.
• July 2026 FDA advisory review: Semax (free base and acetate salt) was reviewed at the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting held July 23–24, 2026 (docket FDA-2025-N-6895) for possible inclusion on the Section 503A list of bulk substances that compounding pharmacies may use. Critically, the FDA's own briefing position recommended AGAINST adding Semax — citing that the substance is not well characterized, has little or no human efficacy data for the proposed (largely injectable) routes, and has insufficient human safety and immunogenicity data.^[11]
• What this means: this was an advisory review that leaned negative, not an approval and not an impending one. Anyone telling you Semax is "about to become legal/compoundable" is misreading the situation. In the US it remains research-only.
• Update — the committee voted anyway: despite that negative staff briefing, the PCAC voted 8–5–1 on July 24, 2026 to recommend adding Semax to the 503A list — based on a review of cerebral ischemia, migraine, and trigeminal neuralgia, not the cognitive/nootropic use most people actually take it for. See the FDA advisory panel's July 2026 vote on semax for the complete two-day record.

For the complete legal picture, read Are Peptides Legal?

Storage

• Russian-manufactured nasal spray: store at 2–8°C; do not freeze; use within the labeled expiration.
• Lyophilized powder (research vial): -20°C long-term; 2–8°C short-term.
• Reconstituted solution: refrigerate at 2–8°C and use within a few weeks; do not freeze.
• Protect from light, and discard anything cloudy or discolored.

See the full peptide storage guide for details.

Semax variants: NA-Semax and NA-Semax Amidate

Two modified versions circulate in the research-peptide world:

• NA-Semax (N-Acetyl Semax): the N-terminus is acetylated to resist enzymatic breakdown, reportedly extending duration of action.
• NA-Semax Amidate: adds C-terminal amidation on top of the N-acetylation for further stability against carboxypeptidase degradation.

Be clear-eyed here: these variants have not undergone formal clinical trials. The reduced doses often suggested for them (roughly 50–70% of standard Semax) come from research-community convention, not published human pharmacokinetic data. Standard, unmodified Semax is the form with the actual clinical track record and regulatory approval in Russia.

Semax vs. Selank

Factor	Semax	Selank
Origin	ACTH(4-10) analog	Tuftsin analog
Overall feel	Mildly activating — focus, drive	Mildly calming — reduces anxiety without sedation
Best-matched goal	Attention, memory, neuroprotection	Anxiety, stress resilience
Combined?	Frequently paired in the Cognitive Stack for complementary focus + calm

Read the full Semax vs Selank comparison.